Unknown AccessWire

Unknown AccessWire is a news wire service that provides press releases and other corporate communications to the financial community and general public. It is known for distributing timely and accurate information about various companies, including their financial results, business updates, and clinical trials. In this case, Unknown AccessWire has provided information about an article related to Moderna's financial results and business updates as well as a biopharma company called MindBio Therapeutics' women's health trials. The author of the article is not specified in the provided data.

100%

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

95%

Examples:

  • Expected product sales for 2024 are approximately $4 billion
  • Moderna expects U.S. approval for its vaccine against respiratory syncytial virus on May 12, with launch expected in the third quarter.
  • Moderna intends to file for approval of its flu vaccine with regulators this year.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

Moderna Defies Expectations with Strong Q1 Financials and EU Vaccine Deal, Despite Stock Slump

Moderna Defies Expectations with Strong Q1 Financials and EU Vaccine Deal, Despite Stock Slump

Broke On: Thursday, 02 May 2024 Moderna reports Q1 financial results with lower-than-expected loss per share and surpassing sales expectations, thanks to strong Covid vaccine sales. The EU plans to purchase up to 36 million doses annually for four years. Moderna is preparing launches for its RSV vaccine and Spikevax 2024-2025 formula, with potential FDA approval for the RSV vaccine later this quarter.